FEMSA Schedules Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Written by Customer Service on February 8, 2024. Posted in Public Companies.

MONTERREY, Mexico, Feb. 08, 2024 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) is pleased to invite you to participate in its Fourth Quarter and Full Year 2023 Conference Call that will be held on: Friday, February 23, 202410:00 AM Eastern Time(9:00 AM Mexico City Time) To participate in the conference call please dial:Toll Free US: (866) 580 3963International: +1 (786) 697 3501Conference ID: FEMSA The quarterly results will be released on February 23 before markets open. The conference call will be webcast live through streaming audio. For details, please visit http://ir.femsa.com If you are unable to participate live, the conference call replay will be available on http://ir.femsa.com/results.cfm About FEMSAFEMSA is a company that creates economic...

Crew Energy Announces 2023 Reserves, 2024 Capital Budget and Guidance

Written by Customer Service on February 8, 2024. Posted in Public Companies.

CALGARY, Alberta, Feb. 08, 2024 (GLOBE NEWSWIRE) — Crew Energy Inc. (TSX: CR; OTCQB: CWEGF) (“Crew” or the “Company”), a growth-oriented natural gas weighted producer operating in the world-class Montney play in northeast British Columbia (“NE BC”), is pleased to announce the results of our year-end 2023 independent reserves evaluation along with our 2024 capital expenditure budget and guidance. Crew’s 2024 budget builds on the success of our 2023 drilling program, efficient execution and asset development, all of which are demonstrated by growth in our 2023 independent reserves evaluation. Production averaged 30,928 boe per day1 in the final quarter of 2023, a 15% increase from 26,834 boe per day1 in Q3/23 and in-line with guidance of 30,000 to 32,000 boe per day. The Company invested approximately $54...

Looking Glass Labs Closes Definitive Agreement to Acquire Bot Media Corp.’s Climate and AI Web3 Assets

Written by Customer Service on February 8, 2024. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) — Looking Glass Labs Ltd. (“LGL” or the “Company”) (NEO: NFTX) (OTC: LGSLF) (FRA: H1N) is pleased to announce that further to the new release dated February 6, 2024, it has closed the definitive agreement (the “Purchase Agreement“), to acquire the climate and artificial intelligence (AI) web3 assets (the “Purchased Assets“) from Bot Media Corp. (the “Vendor”). Pursuant to the Purchase Agreement, the Company has issued an aggregate of 3,060,000 common shares at a deemed price of $0.25 per common share to the Vendor in full satisfaction of the purchase price of $765,000. The securities issued pursuant to the Purchase Agreement have a statutory hold period in accordance with applicable securities laws which will expire on June...

Fortis Inc. Announces Second Quarter Dividends – 2024

Written by Customer Service on February 8, 2024. Posted in Dividend Reports And Estimates.

This news release constitutes a “Designated News Release” incorporated by reference in the prospectus supplement dated September 19, 2023 to Fortis’ short form base shelf prospectus dated November 21, 2022. ST. JOHN’S, Newfoundland and Labrador, Feb. 08, 2024 (GLOBE NEWSWIRE) — The Board of Directors of Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS) has declared the following dividends payable on June 1, 2024 to the Shareholders of Record of the following Shares of the Corporation at the close of business on May 17, 2024: $0.3063 per share on the First Preference Shares, Series “F”; $0.3826875 per share on the First Preference Shares, Series “G”; $0.11469 per share on the First Preference Shares, Series “H”; $0.408392 per share on...

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Written by Customer Service on February 8, 2024. Posted in Public Companies.

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual Presentation Date: Wednesday, February 14, 2024 Time: 9:20 – 9:50am Eastern Time Webcast access: The live-streamed webcast can be accessed here Presentation links can be found in the “News and Media” section of the corporate website. One-on-one meetings may be scheduled directly with Molecular Templates. About Molecular Templates Molecular Templates is a clinical-stage biopharmaceutical company...

Trisura Group Reports Fourth Quarter And 2023 Annual Results

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

TORONTO, Feb. 08, 2024 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the fourth quarter and year ended December 31, 2023. David Clare, President and CEO of Trisura, stated, “Trisura ended the year with strong operational performance. Operating net income of $25.9 million in the quarter, or $0.54 per share, was achieved through measured growth, profitable underwriting and enhanced investment income – supporting annual operating net income of over $110 million. Quarterly Net income of $11.3 million, or $0.23 per share, was impacted by the run-off of a US program, partially offset by unrealized gains in the investment portfolio. Maturation of our business and continued expansion with distribution partners drove insurance...

Interfor Reports Q4’23 Results

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

Adjusted EBITDA loss of $51 million and Net Loss of $169 million BURNABY, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) recorded a Net loss in Q4’23 of $169.0 million, or $3.29 per share, compared to a Net loss of $42.4 million, or $0.82 per share in Q3’23 and a Net loss of $72.2 million, or $1.40 per share in Q4’22. Adjusted EBITDA was a loss of $51.4 million on sales of $785.9 million in Q4’23 versus Adjusted EBITDA of $31.9 million on sales of $828.1 billion in Q3’23 and an Adjusted EBITDA loss of $68.7 million on sales of $810.3 million in Q4’22. Notable items: Weak Lumber Market Lumber prices continued to reflect an imbalance of lumber supply and demand, with demand continuing to be impacted by the elevated interest rate environment and ongoing economic...

Saputo Reports Financial Results for the Third Quarter of Fiscal 2024 Ended December 31, 2023

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

MONTREAL, Feb. 08, 2024 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the third quarter of fiscal 2024, which ended on December 31, 2023. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS). “In the third quarter, we continued to execute with discipline and advance our long-term strategy in a dynamic macroeconomic environment, characterized by volatile commodity markets and a resilient but cautious consumer. Importantly, our continued focus on managing the factors within our control resulted in strong operating cash flow,” said Lino A. Saputo, Chair of the Board, President, and CEO. “We are making tangible...

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Written by Customer Service on February 8, 2024. Posted in Public Companies.

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of its previously announced underwritten public offering of 5,535,055 shares of its common stock. Each share of common stock was sold at a price to the public of $2.71 per share. The gross proceeds to ImmixBio from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ImmixBio. The Company intends to use the net proceeds from this offering for NXC-201 clinical trials, working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners,...

Prospect Capital Announces December 2023 Financial Results and Declares 80th Consecutive $0.06 Dividend

Written by Customer Service on February 8, 2024. Posted in Earnings Releases And Operating Results.

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2023. FINANCIAL RESULTS All amounts in $000’s except per share amounts (on weighted average basis for period numbers) Quarter Ended Quarter Ended Quarter Ended December 31, 2023 September 30, 2023 December 31, 2022 Net Investment Income (“NII”) $96,927 $125,612 $106,704 NII per Common Share $0.24 $0.31 $0.27 Interest as % of Total Investment Income 92.3% 85.7% 89.6% Net Income (Loss) Applicable to Common Shareholders $(51,436) $94,011 $55,623 Net Income (Loss) per Common Share $(0.13) $0.23 $0.14 Distributions to Common...

Day: February 8, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice